Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, July 17, 2013

Ultrasound could be best treatment for acute ischemic stroke

With the pathetic percentage use of tPA, this could be helpful. Although by breaking down the clot are they just pushing the problem down to the smaller arteries?
http://www.labmate-online.com/news/laboratory-products/3/breaking_news/ultrasound_could_be_best_treatment_for_acute_ischemic_stroke/26040/
A new Phase III clinical trial has begun at the University of Texas Health Science Center (UTHealth), which is researching a new treatment for acute ischemic stroke. The clinical trial is exploring the use of a clot-busting medicine used in conjunction with ultrasound to break down blood clots which can lead to further strokes.

The Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator for Emergent Revascularization in Acute Ischemic Stroke (CLOTBUST-ER) trial is a fully randomised, placebo-controlled, double-blinded study. Phase III will include 830 patients across the world. The trial is to use a revolutionary technique, which combines the use of ultrasound and medication to break down blood clots.

Currently the only treatment available for the treatment of a stroke that is caused by a blood clot within an artery is intravenous tissue plasminogen activator (tPA). This treatment is used within the first three hours of the stroke occurring and can result in one-in-three patients experiencing improvements after prompt treatment, or have their symptoms resolved. However, tPA is not suitable for all patients and cannot be administered after the three-hour point of symptoms occurring.

The trial will use tPA alongside transcranial Doppler ultrasound energy to breakdown the arterial blood clots that lead to further complications and symptoms of acute ischemic stroke. UTHealth was the first establishment to look into the use of ultrasound for the treatment of arterial blood clots and the institution conducted a Phase II safety and efficacy study, the results of which were published in 2004 in the New England Journal of Medicine.

This study found that the combined use of ultrasound and tPA resulted in a 38 per cent rate of arterial recanalisation, in comparison to using tPA on its own, which resulted in a 13 per cent rate of arterial recanalisation.

Doctor Andrew Barreto, assistant professor of neurology at the UTHealth Medical School and the North American principal investigator of the Phase III trial, said: “We hope this will be the definitive trial to see if the delivery of ultrasound in combination with tPA results in better outcomes than the use of tPA alone. We will be assessing if the treatment leads to less disability and more independence for stroke victims.” 
A new Phase III clinical trial has begun at the University of Texas Health Science Center (UTHealth), which is researching a new treatment for acute ischemic stroke. The clinical trial is exploring the use of a clot-busting medicine used in conjunction with ultrasound to break down blood clots which can lead to further strokes.
The Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator for Emergent Revascularization in Acute Ischemic Stroke (CLOTBUST-ER) trial is a fully randomised, placebo-controlled, double-blinded study. Phase III will include 830 patients across the world. The trial is to use a revolutionary technique, which combines the use of ultrasound and medication to break down blood clots.
Currently the only treatment available for the treatment of a stroke that is caused by a blood clot within an artery is intravenous tissue plasminogen activator (tPA). This treatment is used within the first three hours of the stroke occurring and can result in one-in-three patients experiencing improvements after prompt treatment, or have their symptoms resolved. However, tPA is not suitable for all patients and cannot be administered after the three-hour point of symptoms occurring.
The trial will use tPA alongside transcranial Doppler ultrasound energy to breakdown the arterial blood clots that lead to further complications and symptoms of acute ischemic stroke. UTHealth was the first establishment to look into the use of ultrasound for the treatment of arterial blood clots and the institution conducted a Phase II safety and efficacy study, the results of which were published in 2004 in the New England Journal of Medicine. This study found that the combined use of ultrasound and tPA resulted in a 38 per cent rate of arterial recanalisation, in comparison to using tPA on its own, which resulted in a 13 per cent rate of arterial recanalisation.
Doctor Andrew Barreto, assistant professor of neurology at the UTHealth Medical School and the North American principal investigator of the Phase III trial, said: “We hope this will be the definitive trial to see if the delivery of ultrasound in combination with tPA results in better outcomes than the use of tPA alone. We will be assessing if the treatment leads to less disability and more independence for stroke victims.”   
- See more at: http://www.labmate-online.com/news/laboratory-products/3/breaking_news/ultrasound_could_be_best_treatment_for_acute_ischemic_stroke/26040/#sthash.GPcXUa3b.dpuf
A new Phase III clinical trial has begun at the University of Texas Health Science Center (UTHealth), which is researching a new treatment for acute ischemic stroke. The clinical trial is exploring the use of a clot-busting medicine used in conjunction with ultrasound to break down blood clots which can lead to further strokes.
The Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator for Emergent Revascularization in Acute Ischemic Stroke (CLOTBUST-ER) trial is a fully randomised, placebo-controlled, double-blinded study. Phase III will include 830 patients across the world. The trial is to use a revolutionary technique, which combines the use of ultrasound and medication to break down blood clots.
Currently the only treatment available for the treatment of a stroke that is caused by a blood clot within an artery is intravenous tissue plasminogen activator (tPA). This treatment is used within the first three hours of the stroke occurring and can result in one-in-three patients experiencing improvements after prompt treatment, or have their symptoms resolved. However, tPA is not suitable for all patients and cannot be administered after the three-hour point of symptoms occurring.
The trial will use tPA alongside transcranial Doppler ultrasound energy to breakdown the arterial blood clots that lead to further complications and symptoms of acute ischemic stroke. UTHealth was the first establishment to look into the use of ultrasound for the treatment of arterial blood clots and the institution conducted a Phase II safety and efficacy study, the results of which were published in 2004 in the New England Journal of Medicine. This study found that the combined use of ultrasound and tPA resulted in a 38 per cent rate of arterial recanalisation, in comparison to using tPA on its own, which resulted in a 13 per cent rate of arterial recanalisation.
Doctor Andrew Barreto, assistant professor of neurology at the UTHealth Medical School and the North American principal investigator of the Phase III trial, said: “We hope this will be the definitive trial to see if the delivery of ultrasound in combination with tPA results in better outcomes than the use of tPA alone. We will be assessing if the treatment leads to less disability and more independence for stroke victims.”   
- See more at: http://www.labmate-online.com/news/laboratory-products/3/breaking_news/ultrasound_could_be_best_treatment_for_acute_ischemic_stroke/26040/#sthash.GPcXUa3b.dpuf

No comments:

Post a Comment